Innovative Technology CorInnova is developing a cutting-edge, minimally invasive soft robotic cardiac assist device that has the potential to revolutionize heart failure treatment by increasing cardiac output by up to 50%. This innovative approach opens opportunities for hospitals and clinics seeking advanced therapies for severe heart failure cases.

Expanding Market Potential With an addressable market estimated at up to $10 billion, CorInnova's device presents a significant revenue opportunity for medical device distributors and hospital procurement teams aiming to expand their portfolio with next-generation cardiovascular solutions.

Strategic Funding Support Backed by prominent investors such as Wellcome Trust, CorInnova demonstrates strong financial and strategic backing, indicating a viable pathway to commercialization. Sales teams can leverage this credibility when engaging with healthcare providers and stakeholders.

Focus on Heart Failure CorInnova's targeted focus on reversing and preventing heart failure aligns well with the growing demand for innovative, minimally invasive cardiac therapies, providing sales opportunities in specialty hospitals and cardiovascular centers focused on advanced heart failure treatment.

Active Development Stage Currently involved in ongoing development and clinical validation, CorInnova offers opportunities for early engagement with key opinion leaders and early adopters, making it an attractive partner for institutions and clinicians invested in groundbreaking cardiac technology.